4/9
08:50 am
aktx
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC
Medium
Report
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC
4/8
08:28 am
aktx
Akari Therapeutics (AKTX) was downgraded by Maxim Group from "buy" to "hold".
Low
Report
Akari Therapeutics (AKTX) was downgraded by Maxim Group from "buy" to "hold".
4/6
08:45 am
aktx
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
High
Report
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
4/2
08:01 am
aktx
Akari Therapeutics (AKTX) had its price target raised by HC Wainwright from $1.60 to $27.00. They now have a "buy" rating on the stock.
Medium
Report
Akari Therapeutics (AKTX) had its price target raised by HC Wainwright from $1.60 to $27.00. They now have a "buy" rating on the stock.
3/18
08:05 am
aktx
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
High
Report
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
3/17
04:30 pm
aktx
Akari Therapeutics Announces ADS Ratio Change
High
Report
Akari Therapeutics Announces ADS Ratio Change
3/13
09:15 am
aktx
Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala
High
Report
Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala
2/26
09:10 am
aktx
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
Low
Report
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
2/23
08:50 am
aktx
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board
Medium
Report
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board
2/18
09:05 am
aktx
Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference
Medium
Report
Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference
2/11
08:45 am
aktx
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline
Low
Report
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline
2/5
09:15 am
aktx
Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Low
Report
Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
1/26
08:45 am
aktx
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
Low
Report
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors